Adverse Events of Special Interest in Patients with Advanced Basal Cell Carcinoma Receiving Sonidegib: Long-Term 42-Month Results from the BOLT Study

Main Article Content

Alexander Guminski
Nicholas Squittieri
John T Lear


Basal Cell carcinoma, Sonidegib, adverse effects


Abstract not available.


1. Migden MR, et al. Lancet Oncol. 2015;16(6):716–28.

2. Odomzo (sonidegib) [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2017.

3. Australian Government Department of Health, ARTG 292262.

4. European Medicines Agency. Summary of Product Characteristics, WC500188762.

5. Swissmedic, Authorization Number 65065, 2015.

6. Migden MR, et al. J Clin Oncol. 2018; 36: Suppl abstr 9551.

7. Lear JT, et al. J Eur Acad Dermatol Venereol. 2018; 32 (3): 372–81.

8. Dummer R, et al. J Am Acad Dermatol. 2016; 75 (1): 113–25 e5.

9. Dummer R, et al. Br J Dermatol. 2019; 10.1111/bjd.18552.

10. Eisenhauer EA, et al. Eur J Cancer. 2009; 45 (2): 228–47.

11. World Health Organization.

12. National Cancer Institute. Common Terminology Criteria for Adverse Events v4.03.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)